Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Phase 2TerminatedNCT00003516

Burzynski Research Institute16 enrolled

Overview

Current therapies for Stage III or Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage III or Stage IV Prostate Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage III or Stage IV Prostate Cancer.

Stage III or Stage IV Prostate Cancers receive Antineoplaston A10 and AS2-1 capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. OBJECTIVES: * To determine the efficacy of Antineoplaston therapy in patients with Stage III or Stage IV Prostate Cancer, as measured by an objective response to therapy (complete response, partial response or stable disease). * To determine the safety and tolerance of Antineoplaston therapy in patients with Stage III or Stage IV Prostate Cancer. * To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 4 months for 2 years, every 6 months for 2 years, and then annually for 2 years thereafter.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

Antineoplaston therapy (Atengenal + Astugenal)DRUG

Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Histologically proven stage III or IV adenocarcinoma of the prostate not potentially curable by surgery or radiotherapy * Measurable tumors or tumor markers * No response to antiandrogen withdrawal PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 60-100% Life expectancy: * At least 3 months Hematopoietic: * WBC at least 3000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 2.5 mg/dL * SGOT no greater than 2 times normal * No hepatic failure Renal: * BUN less than 60 mg/dL * Creatinine no greater than 2.5 mg/dL OR * Creatinine clearance greater than 60 mL/min * Blood ammonia normal * No chronic renal failure Cardiovascular: * No severe heart disease Pulmonary: * No severe lung disease Other: * Fertile patients must use effective contraception during and for 4 weeks after study participation * No serious active infection or fever * No other concurrent serious disease * No other prior or concurrent malignancy within the past 2 years PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior immunotherapy and recovered Chemotherapy: * At least 4 weeks since prior chemotherapy and recovered Endocrine therapy: * At least 4 weeks since prior hormonal therapy and recovered * Prior corticosteroids for at least 2 months allowed, but must be on stable or decreasing dose during study participation Radiotherapy: * See Disease Characteristics * At least 4 weeks since prior radiotherapy and recovered Surgery: * See Disease Characteristics * At least 4 weeks since prior surgery and recovered Other: * At least 4 weeks since prior experimental clinical trial * No other concurrent therapy for metastatic disease

Locations (1)

Burzynski Clinic

Houston, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.